The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.16
Bid: 2.09
Ask: 2.20
Change: -0.055 (-2.50%)
Spread: 0.11 (5.263%)
Open: 2.07
High: 2.16
Low: 2.07
Prev. Close: 2.20
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

30 Nov 2005 13:38

General Industries PLC30 November 2005 General Industries plc Interim Results for the six months ended 30 September 2005 Registered number 03929567 Chairman's Statement General Industries plc is quoted on AIM with a strategy to acquire one or moregrowing, unquoted companies that wish to seek capital for expansion of theirbusiness and a public market for their shares. For the six months ended 30 September 2005, turnover was £nil (2004: £nil).Profit before taxation was £8,813 (2004: £8,383) and comprised interest fromcash on deposit of £23,550 (2004: £21,812) less administrative expenses of£14,737 (2004: £13,429). Profit after taxation amounted to £7,907 (2004:£6,790). Earnings per share was 0.19p (2004: £0.16p). The directors do not recommend a dividend. During the period under review further potential acquisitions were analysedincluding companies in the debt factoring, recruitment, telecommunications andpharmaceutical fields. In one case the potential candidate proceeded with itsown IPO at a higher capital value than that attributed by your Directors. Wecontinue to analyse and investigate other suitable acquisitions. The rating of smaller companies quoted on the Alternative Investment Market hassuffered a setback over recent months and it is therefore important to valuepotential acquisitions at realistic levels. J Richard WollenbergChairman 30 November 2005 Profit and Loss Accountfor the six months ended 30 September 2005 Six months Six months Year 30 September 30 September 31 March 2005 2004 2005 (Unaudited) (Unaudited) (Audited) £ £ £ Administrative expenses being loss onordinary activities before interest (14,737) (13,429) (28,774)Interest receivable and similar income 23,550 21,812 45,411 --------- --------- -------- Profit on ordinary activities beforetaxation 8,813 8,383 16,637Tax on profit on ordinary activities (906) (1,593) (1,576) --------- --------- -------- Profit on ordinary activities aftertaxation being profit for thefinancial period 7,907 6,790 15,061 ========= ========= ======== Earnings per shareOn profit for the periodBasic 0.19 0.16 0.36Diluted 0.18 0.16 0.36 ========= ========= ======== The above results relate entirely to continuing activities. There were noacquisitions or disposals of businesses in the period. Balance Sheetat 30 September 2005 At 30 At 30 At 31 September September March 2005 2004 2005 (Unaudited) (Unaudited) (Audited) £ £ £Current assetsDebtors 2,456 - 1,806Cash at bank and in hand 1,010,244 992,683 1,005,312 --------- --------- -------- 1,012,700 992,683 1,007,118Creditors: amounts falling due withinone year (11,352) (7,513) (13,677) --------- --------- -------- Net current and net assets 1,001,348 985,170 993,441 ========= ========= ======== Capital and reservesCalled up share capital 420,000 420,000 420,000Share premium account 557,003 557,003 557,003Profit and loss account 24,345 8,167 16,438 --------- --------- -------- Shareholders' funds - equity 1,001,348 985,170 993,441 ========= ========= ======== Net assets per share 23.8p 23.5p 23.7p ========= ========= ======== Cash Flow Statementfor the six months ended 30 September 2005 Six months Six months Year 30September 30 September 31 March 2005 2004 2005 (Unaudited) (Unaudited) (Audited) £ £ £ Cash outflow from operating activities (16,570) (7,331) (18,301)Returns on investment and servicing offinance 23,550 21,812 45,411Taxation (2,048) - - --------- --------- -------- --- --- ---Cash inflow before financing 4,932 14,481 27,110Financing - - - --------- --------- -------- Increase in cash in the period 4,932 14,481 27,110 ========= ========= ======== Reconciliation of Net Cash Flow to Movement in Net Funds Six months Six months Year 30 September 30 September 31 March 2005 2004 2005 (Unaudited) (Unaudited) (Audited) £ £ £Increase in cash and movement in netfunds in the period resulting fromcash flows 4,932 14,481 27,110Net funds at beginning of period 1,005,312 978,202 978,202 --------- --------- -------- Net funds at end of period 1,010,244 992,683 1,005,312 ========= ========= ======== Reconciliation of Operating Loss to Net Cash Flow from Operating Activitiesfor the six months ended 30 September 2005 Six months Six months Year 30 September 30 September 31 March 2005 2004 2005 (Unaudited) (Unaudited) (Audited) £ £ £ Operating loss (14,737) (13,429) (28,774)(Increase)/decrease in debtors (649) 1,718 (88)(Decrease)/increase in creditors (1,184) 4,380 10,561 --------- --------- -------- (16,570) (7,331) (18,301) ========= ========= ======== Notes to the Financial Statementsfor the six months ended 30 September 2005 1 Basis of preparation The figures for the six months ended 30 September 2005, which were approved bythe board on ** November 2005, are prepared on the same basis of accounting asfor the year ended 31 March 2005 and are unaudited. The comparative figures for the financial year ended 31 March 2005 are not thecompany's statutory accounts for that financial year. Those accounts have beenreported on by the company's auditors and delivered to the registrar ofcompanies. The report of the auditors was (i) unqualified, (ii) did not includea reference to any matters to which the auditors drew attention by way ofemphasis without qualifying their report and (iii) did not contain a statementunder section 237(2) or (3) of the Companies Act 1985. 2 Dividends As stated in the prospectus, the directors do not intend to pay any dividenduntil completion of a significant acquisition. Following such an acquisition,the directors will determine an appropriate dividend policy. 3 Taxation The tax position for the six months is estimated on the basis of the anticipatedtax rates applying for the full year. Reconciliation of Movement in Shareholders' Funds At 30 At 30 At 31 September September March 2005 2004 2005 (Unaudited) (Unaudited) (Audited) £ £ £ At beginning of period 993,441 978,380 978,380Profit after tax for the period 7,907 6,790 15,061 --------- --------- -------- 1,001,348 985,170 993,441 ========= ========= ======== This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Jul 20217:00 amRNSBoard Changes
16th Jul 20217:00 amRNSBoard Appointment
28th Jun 202112:27 pmRNS2021 RESULT OF ANNUAL GENERAL MEETING -REPLACEMENT
28th Jun 202111:03 amRNS2021 RESULT OF ANNUAL GENERAL MEETING
24th Jun 20214:41 pmRNSSecond Price Monitoring Extn
24th Jun 20214:36 pmRNSPrice Monitoring Extension
24th Jun 20217:00 amRNSUpdate: Lupzuor™ PK study
2nd Jun 20217:00 amRNSNotice of AGM and posting of Report & Accounts
24th May 20217:00 amRNSDirector Retirement
29th Apr 20214:35 pmRNSPrice Monitoring Extension
29th Apr 20217:00 amRNSFinal Results
16th Apr 20214:41 pmRNSSecond Price Monitoring Extn
16th Apr 20214:36 pmRNSPrice Monitoring Extension
25th Feb 20214:41 pmRNSSecond Price Monitoring Extn
25th Feb 20214:35 pmRNSPrice Monitoring Extension
9th Feb 20217:00 amRNSUpdate- scheduled Phase 3 trials in lupus patients
18th Jan 20217:00 amRNSAppointment of Company Secretary
4th Jan 20217:00 amRNSHolding(s) in Company
2nd Dec 20207:00 amRNSIMM TO PRESENT AT BIOTECH SHOWCASE DIGITAL 2021
30th Nov 20207:00 amRNSTotal Share Capital Notification
26th Nov 20207:00 amRNSGrant of Share Options & PDMR dealing
24th Nov 20207:00 amRNSConversion of Convertible Security
23rd Nov 20207:00 amRNSConversion of Convertible Security
20th Nov 20207:00 amRNSUpdate : FDA confirms 4 Dec for Type ‘A’ meeting
18th Nov 20207:00 amRNSTotal Share Capital Notification - Replacement
10th Nov 20207:00 amRNSUpdate on submission to the FDA
30th Sep 20207:01 amRNSTotal Share Capital Notification
30th Sep 20207:00 amRNSInterim Results
29th Sep 20207:00 amRNSShare Subscription into Incanthera plc
22nd Sep 20207:00 amRNSRepayment of Convertible Security
11th Sep 20207:59 amRNSUpdate on submission to the FDA
10th Sep 202010:59 amRNSConversion of Convertible Security
9th Sep 20201:45 pmRNSConversion of Convertible Security
8th Sep 20203:49 pmRNSHolding(s) in Company
8th Sep 20209:00 amRNSDirector/PDMR Shareholding / TR -1
7th Sep 20207:02 amRNSPlacing - update; related party transaction)
3rd Sep 20207:00 amRNSConversion of Convertible Security
2nd Sep 20207:00 amRNSPlacing to raise £6.5 million
1st Sep 20207:00 amRNSHolding(s) in Company
27th Jul 20207:00 amRNSFDA submission for Special Protocol Assessment
18th Jun 202011:31 amRNS2020 AGM – ALL RESOLUTIONS PASSED
16th Jun 20207:00 amRNSTotal Share Capital Notification
11th Jun 202012:00 pmRNSTR-1 Notification of major holdings
11th Jun 20207:00 amRNSSTRAT. INVTS FROM 2 SPECIALIST US H'CARE INVESTORS
5th Jun 20207:00 amRNSChange of Registered Office Address
2nd Jun 20207:00 amRNSNotification of Change of AGM Venue
21st May 20207:00 amRNSNotice of AGM and posting of Report & Accounts
18th May 20201:45 pmRNSTR-1: Notification of major holdings
14th May 20207:00 amRNSEfforts in fight vs Covid-19 with Lupuzor; Ureka
30th Apr 20209:57 amRNSAudited Report & Accounts published on website

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.